--- title: "UTHR Chair Rothblatt Exercises Options, Sells $9.2M in 5 Days" type: news slug: uthr-rothblatt-options-exercise-9m-may-2026 canonical_url: https://13finsight.com/news/uthr-rothblatt-options-exercise-9m-may-2026 published_at: 2026-05-14T06:10:36.636Z updated_at: 2026-05-14T06:10:39.616Z author: Alex Rivera author_title: Breaking News Editor author_url: https://13finsight.com/authors/alex-rivera word_count: 911 locale: en source: 13F Insight --- # UTHR Chair Rothblatt Exercises Options, Sells $9.2M in 5 Days > Martine Rothblatt, chair and CEO of United Therapeutics, exercised 28,500 options at $146.03 and sold 16,016 shares for $9.23M across five trading sessions through May 11, 2026. The transaction profile is consistent with a cashless exercise — not a discretionary exit. Martine Rothblatt, the founder, chairperson, and chief executive of United Therapeutics, just put a five-session block of Form 4 transactions on the SEC tape. Between May 7 and May 11, 2026, she exercised 28,500 stock options at a $146.03 strike and sold 16,016 shares for roughly $9.23 million at prices clustered between $574 and $580 per share. The latest filing (accession 0001106578-26-000051) shows 15,288 shares remaining directly held on the non-derivative line after the sequence. The transaction profile is what matters here. This is not a discretionary exit, and it is not a thesis-change tape. It is a textbook exercise-and-sell: roughly $431 of intrinsic spread per share between the option strike and the market clearing price, with the sold tranche covering both the option cost and the resulting tax bill. The framing of the trade matters — see Rothblatt's full Form 4 trading history for the multi-year pattern. Reading the Five-Day Sequence Twenty-seven sale tranches across five sessions is a mechanical pattern. A discretionary CEO selling $9M of stock would not split a position into a stair-step of 100-to-1,000 share clips — that is the signature of an automated execution algorithm working in line with a pre-arranged framework, even though the filing itself does not carry an explicit Rule 10b5-1 plan footnote. The exercises (`M` transaction code, 28,500 shares at $146.03) sit alongside sales (`S` transaction code, 16,016 shares at $574–580) inside the same accession number, which is the formal sign that this was a single, structured exercise-and-sell event rather than two separate discretionary decisions. Net of the exercise, Rothblatt's directly-held non-derivative position changed from approximately 2,804 shares (pre-sequence) to 15,288 shares reported after the final May 11 transaction. The headline narrative — "insider sells" — misses the structure: she added net 12,484 shares to direct ownership through the exercise side of the transaction. The cash proceeds from the sale tranche covered the option strike cost (28,500 × $146.03 = $4.16M) and a meaningful slice of the marginal-rate tax liability on the spread. What the 13D/G Record Adds 13F Insight's filings dataset shows two recent 13G filings on UTHR that contextualize the institutional backdrop into which Rothblatt is exercising: Wellington Management Group LLP — 13G filed 2026-02-10, 5.700% / 2,441,492 shares. Wellington's appearance crossing the 5% threshold on UTHR is the kind of long-only institutional accumulation that typically precedes share-price re-rates on biotech names with a maturing commercial pipeline. Vanguard Capital Management LLC — 13G filed 2026-04-30, 5.190% / 2,278,348 shares. This is the post-Vanguard-restructuring sub-account filing — index-mandate exposure, not active conviction. Note the same form on the same security from "Vanguard Group Inc" went to 0.000% in March 2026 as the Vanguard book restructured into sub-account filers. The cleanest read: a 5.7% Wellington position is what an exercising CEO chair wants to see on her cap table when she's pulling forward $9M of pre-tax spread. The Wellington filing is the active-money endorsement; Rothblatt's exercise is happening into stable institutional sponsorship rather than against active distribution. The Macro Context: A Pulmonary-Hypertension Franchise at New Highs United Therapeutics is the rare biotech that operates a profitable, commercial pulmonary arterial hypertension (PAH) franchise — Remodulin, Tyvaso, and the dry-powder inhalation extensions — rather than a pipeline-stage R&D book. The stock crossing into the $570–580 range coincides with continued execution on the Tyvaso DPI uptake and the company's organ manufacturing initiative, which is the optionality story bolted onto an already-cash-generative core. Against that operating backdrop, the exercise math is doing what it is supposed to do. The $146.03 strike was set when the stock traded materially lower; at $577, the intrinsic spread per share is roughly 3.95×. Founder-CEOs exercising older option tranches into a high-water price print are doing strike management, not signaling distress. The historical Form 4 cadence on Rothblatt's career insider page shows a consistent pattern of exercising long-dated options as they approach expiration windows. What Would Change the Read Three concrete things would convert this from a routine exercise-and-sell into a meaningful insider signal: A standalone `S` filing with no companion `M`. A discretionary open-market sale separated from any exercise event would be the cleanest distress signal. The current accession ties the sales to the exercises in a single filing. A sustained acceleration in selling cadence. The trailing-90-day Form 4 record on UTHR insiders is the right comparison set — a step-change in volume or frequency relative to that baseline is the trigger. A coordinated multi-officer exit. If the CFO, COO, or other named executive officers file similar exercise-and-sell sequences in the same window, the pattern shifts from individual strike management to a coordinated executive monetization. Track insider activity across the UTHR officer set for that. Forward Anchors Two verifiable upcoming windows: Next 10-Q filing (UTHR fiscal cycle puts the Q2 2026 10-Q in early August 2026). The Tyvaso DPI revenue line is the operating anchor that determines whether Wellington's recently-disclosed 5.7% stake adds or trims. Form 144 disclosures. Any Form 144 filings from Rothblatt or other UTHR executives become visible on EDGAR ahead of larger discretionary sales. The absence of a Form 144 paired with this exercise sequence is itself a tell that the structure was option-cost-and-tax-driven, not pre-flagged discretionary distribution. FAQ The institutional ownership feed for the name lives on the UTHR institutional holders page, and the activist filings register is on the activist 13D/G feed. Both are the right pages to monitor if the framing of Rothblatt's exercise activity is going to change over the next quarter. ## FAQ ### How much UTHR stock did Martine Rothblatt sell? Martine Rothblatt, chair and CEO of United Therapeutics, sold 16,016 UTHR shares for approximately $9.23 million between May 7 and May 11, 2026, at prices clustered between $574 and $580 per share. The sales were paired with 28,500 option exercises at a $146.03 strike inside the same Form 4 accession 0001106578-26-000051. ### Why did Rothblatt exercise UTHR options? The transaction structure is a classic cashless exercise: 28,500 options exercised at $146.03 against a market price near $577 produced roughly $431 per share of intrinsic spread. The sales covered the option strike cost ($4.16M) and a meaningful share of the marginal tax bill on the gain. Net of the exercise, Rothblatt added approximately 12,484 shares to direct ownership. ### How many UTHR shares does Rothblatt own after the sale? Rothblatt's directly-held non-derivative position stands at 15,288 UTHR shares as reported on the May 11, 2026 Form 4. That figure reflects the net effect of the exercise-and-sell sequence and does not include any indirect or trust holdings reported elsewhere in her Form 4 history. ### Are other UTHR insiders selling? 13F Insight's insider activity feed shows no coordinated multi-officer exit at United Therapeutics around the May 2026 window. Wellington Management's recently disclosed 5.7% stake (13G filed 2026-02-10) provides institutional sponsorship context that argues against a defensive insider distribution pattern. --- Source: 13F Insight — https://13finsight.com/news/uthr-rothblatt-options-exercise-9m-may-2026 Author: Alex Rivera — https://13finsight.com/authors/alex-rivera Last updated: 2026-05-14T06:10:39.616Z